Trial of innovative digital infection control solution in Manchester NHS FT ICU

我们的创新解决方案旨在防止医疗保健获得性感染(HCAI)在医院内传播。该项目的目标是在曼彻斯特大学NHS基金会信托基金(MFT)--我们的合作伙伴--的ICU中调查解决方案。这将使我们能够开发该解决方案，对其进行认证，然后将其推向英国和国际上的医疗保健客户，并创建一家世界领先的公司。该解决方案基于数字接触者追踪的概念。其目的是在病原体感染之前发现他们，并将其传播给新的宿主。没有新的宿主，病原体就不能繁衍。我们的解决方案利用了可穿戴技术，快速、准确，能够应对医院中发现的任何传染性病原体。这样的项目对NHS的好处很大。20%的NHS床位被因HCAIs而逾期逗留的患者占据，这些人每年的直接治疗费用为28亿GB。HCAIs每年导致22,000名患者死亡(不包括新冠肺炎)。如果该项目成功，所产生的产品可以将NHS的能力提高5-10%，同时节省10亿GB以上的直接治疗成本。潜在的发达国家医疗保健市场规模巨大(约Proxximos已经在一家工厂建造了一个原型，并获得了剑桥生命科学风险投资公司的投资，并在弗朗西斯·克里克研究所运营的知识季实验室加速器中获得了一席之地。在Innovate UK的帮助下，我们将开始为英国和国际医疗保健市场开发这种医疗产品并将其商业化的旅程。

Our innovative solution is designed to prevent Healthcare Acquired Infections (HCAIs) from spreading around hospitals. The objective of this project is to investigate the solution in the ICU in the Manchester University NHS Foundation Trust (MFT) -- our collaboration partner. This will enable us to develop the solution, certify it and then market it to healthcare customers in the UK and internationally, and create a world-leading company.The solution is based on the concept of digital contact tracing. The aim is to find people infected with a pathogen before they become infectious and spread it to a new host. Without a new host, a pathogen cannot prosper. Our solution exploits wearable technology and is fast, accurate and capable of tackling any communicable pathogen found in a hospital.The benefits of such a project for the NHS are large. 20% of NHS beds are occupied by patients who are overstaying due to HCAIs, and the annual direct treatment costs for these people is £2.8 billion. HCAIs cause 22,000 patient deaths per year (not including Covid-19). If the project is successful, the resulting product could increase NHS capacity by 5-10% whilst saving £1 billion-plus in direct treatment costs. The potential developed world healthcare market is huge (approx. £3 billion).Proxximos has built a prototype in a factory and has secured investment from a Cambridge life sciences VC, and has secured a place in the Knowledge Quarter Labs Accelerator, run by the Francis Crick Institute. With Innovate UK help, we would like to embark on the journey of developing this medical product and commercialising it for healthcare markets in the UK and internationally.